Knowledge and perception.

Psychedelics such as psilocybin, LSD, and MDMA have shown promise in treating mental health conditions (e.g., depression, post-traumatic stress disorder) among neurotypical individuals, i.e., typically developing individuals without a diagnosed neurodevelopmental condition. However, their therapeutic potential for treating co-occurring mental-health conditions in autistic individuals remains under-explored. Autistic individuals often face co-occurring mental health challenges but are frequently excluded from clinical trials, creating a gap in effective treatments. This study aimed to explore knowledge, perceptions, and experiences of autistic adults regarding psychedelics. In this survey, “psychedelics” included classical psychedelics such as psilocybin and LSD, as well as MDMA. A cross-sectional online survey was conducted with English-speaking autistic adults. We assessed participants’ knowledge of psychedelics, willingness to use them for mental health treatment, and any past psychedelic experiences. Data were analyzed using descriptive statistics and chi-square tests to assess group differences. A total of 424 participants began the survey, with 261 completing it. Nearly half resided in Canada. Participants generally viewed psychedelics positively, with 77.8% expressing a willingness to try them, and 69.7% reported past use—most commonly psilocybin mushrooms. Higher doses and highly meaningful experiences correlated with longer-lasting mental health improvements. Barriers included legal concerns, health risks, and logistical challenges. Participants with prior experience reported greater perceived knowledge and lower perceived risks. Autistic adults in this self-selecting sample demonstrated strong interest in psychedelics as potential treatments for mental health, despite significant barriers to access and research participation. These results highlight the importance of considering education, policy reform, and inclusive research practices to ensure that autistic people have opportunities to explore psychedelic therapies. These findings should be interpreted cautiously, as the sample may not be representative of the broader autistic population. Future trials should optimize dosing and explore long-term benefits of psychedelics in this population.